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ABSTRACT
Systemic lupus erythematosus (SLE) is a 
chronic, disabling, progressive disease, 
with many associated comorbidities, af-
fecting patients during prime working 
years resulting in a high economic bur-
den on society, producing high direct, 
indirect and intangible costs.
In this article, our goals are two-fold. 
First, we review and discuss studies 
published in the period 2002–2012 con-
cerning costs of SLE and point out gaps 
in the published literature. Second, 
we propose further research studies to 
advance our understanding of the eco-
nomic perspective in SLE in the current 
area of new and emerging therapies.
The literature evaluating disease costs 
in SLE remains limited and to date has 
only included a small number of coun-
tries. Despite these limitations, avail-
able studies indicate that SLE has sig-
niﬁcant socio-economic ramiﬁcations.
Future studies are needed, especially to 
assess novel biologic therapies which 
have been made available or currently 
under investigation for SLE. An inter-
esting approach in these new economic 
evaluations in SLE may be represented 
by the selection of the targets of the 
treatment to include in the cost-ef-
fectiveness and cost-utility analyses. 
Future treat-to-target strategies will 
likely include evaluation of their phar-
macoeconomic implications. 
Introduction
Systemic lupus erythematosus (SLE) is 
a chronic illness, affecting mainly young 
women during childbearing years (1). 
Over the past decades a marked increase 
in long term patient survival has been 
achieved (2). As patients live longer, at-
tention to the damage resulting from the 
disease, and important co-morbidities 
of SLE and its therapies, such as car-
diovascular disease, osteoporosis and 
cancer, has increased (3-7).
Recently, new drugs are being de-
veloped for the treatment of SLE to 
improve control of activity and qual-
ity of life, and reduce damage accrual 
and glucocorticoid usage (8). If these 
new therapies are shown to improve 
long-term patient outcomes, issues of 
cost-effectiveness are certain to arise, 
as has been seen with the introduction 
of biological agents in the treatment 
of rheumatoid arthritis (RA) and other 
rheumatic diseases (9-14).
In this article, our goals are two-fold. 
First, we review and discuss studies 
published in the period 2002–2012 con-
cerning costs of SLE and point out gaps 
in the literature. Second, we propose 
further studies to advance understand-
ing of the economic perspective in SLE 
in the current era of new and emerging 
therapies.
A systematic literature review of 
the cost dimension of SLE
The objective of this systematic litera-
ture review is to present data concern-
ing the economic burden of this disease. 
The review includes papers published 
over the last decade and is designed in 
accordance with the recommendations 
of the Centre for Reviews and Dissemi-
nation (15) and of the Cochrane Col-
laboration (16), thereby using an estab-
lished rigorous and reproducible meth-
odology. A protocol was developed to 
deﬁne the review question.
Methods
Published studies in English lan-
guage were searched using PubMed 
MEDLINE. The search was performed 
for the period June 2002–June 2012. 
This choice was made to obtain a mod-
ern perspective reﬂective of current dis-
ease outcomes, given advances in pa-
tient management as well as in treatment 
protocols over the last decade (17). The 
search strategy was as follows: (cost 
AND systemic lupus erythematosus) 
AND ((“2002/06/01”[PDat]:”2012/06/
30”[PDat])AND Humans[Mesh] AND 
English[lang]).
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Publications were assessed for inclu-
sion by a three-step-process: i. titles 
and abstracts of all identiﬁed studies 
were assessed by one reviewer and 
re-evaluated by a second reviewer; ii. 
full texts of relevant articles were then 
obtained and inclusion criteria applied 
independently by two reviewers. Pos-
sible discordances between reviewers 
were resolved by consensus; iii. data 
were extracted by one reviewer and re-
evaluated by a second reviewer.
Inclusion criteria
Studies were included in the System-
atic Literature Review based on the fol-
lowing inclusion criteria:
Studies:  all reports on economic evalu-
ation as cost analysis, cost minimisation 
analysis (CMA), cost effectiveness anal-
ysis (CEA), cost utility analysis (CUA) 
and cost beneﬁt analysis (CBA).
Patients: all adult patients (≥18 years) 
regardless disease characteristic or or-
gan manifestation.
Outcomes: direct costs, indirect costs, 
quality of life costs, and cost associated 
with ﬂares. 
Exclusion criteria
Studies not published in English, all 
publications before 2002, reviews, con-
ferences proceedings, case reports, let-
ters and commentaries were excluded. 
In addition, papers referring to the same 
cohorts of patients were excluded.
Papers included in the review
As of July 2012, 121 articles were ex-
tracted by the search procedure. After 
review of the titles, 43 relevant publi-
cations were identiﬁed. These were as-
sessed for eligibility. After reading the 
abstract, 26 publications met inclusion 
criteria and were retrieved for full text 
review. Fourteen articles were included 
in the Systematic Literature Review 
(18-31). Twelve papers were excluded 
for the following reasons: reviews (32, 
35-37, 39), did not provide economic 
data (33, 34, 38, 40-43).
None of the publications provided full 
economic evaluation (CMA, CEA, CUA 
and CBA). Among the studies, differenc-
es were present in terms of target popula-
tion, study design, methodology, perspec-
tive and time horizon of the analysis. 
The systematic literature review is 
based on 7 studies from the USA (20, 
21, 23, 24, 27, 28, 30), 3 from Canada 
(19, 26, 27), 1 from Taiwan (18), 2 
from Hong Kong (22, 25), and 1 from 
Germany (29).
Four included reports are retrospective 
(20-22, 25), 1 is cross-sectional (19), 3 
are longitudinal studies (23, 26, 31), 1 
is community based case-control (21), 
1 is epidemiological (8) and 4 are not 
speciﬁed (18, 27, 29, 30).
Finally, 4 reports include only direct 
costs (18, 20, 23, 31), 7 analyse direct 
and indirect costs (19, 21, 22, 25-27, 
29), 2 examine only indirect costs (24, 
28), and 1 only hospitalisation costs 
(30).
Results
The examined publication only report 
a simple cost analysis as none includes 
data on cost-effectiveness, cost-beneﬁt 
analysis or cost-utility analysis preclud-
ing a full economic evaluation. In addi-
tion, comparison of the results is made 
difﬁcult by a large number of differenc-
es in the target population, severity of 
the disease studied, number of clinical 
manifestations and comorbidities con-
sidered, study design, perspective and 
time horizon of analysis, selection of 
costs/resources to be analysed, method-
ology used to monetise costs/resources, 
data sources (patient self-reported re-
source utilisation vs claims-based anal-
yses; indemnity plans vs. Health main-
tenance organisation plans).
Although comparison between the stud-
ies is difﬁcult, agreement exists on the 
fact that SLE patients consume more 
resources than healthy population. 
Chiu et al. investigated the epidemiol-
ogy and the medical costs of patients 
with SLE in Taiwan from January 2000 
to December 2007. The authors report 
a mean expenditure for each outpatient 
service of US$71.5, and an expenditure 
for each hospitalisation of US$1,922.3. 
In 2007, the last year of analysis, the 
average of total yearly medical costs 
per patient was US$1,660 (18).
Carls et al. retrospectively estimate di-
rect and indirect costs for SLE patients 
and a matched control group of patients 
who do not have SLE. The total direct 
medical expenditure in SLE group is 
$19,502 while in the control group it 
is $7,264. The indirect expenditure in 
terms of absenteeism costs in the 12 
month study period is higher in the 
control group compared to SLE pa-
tients ($4,018 vs. $3,469) (21).
Zhu et al. retrospectively evaluated di-
Fig. 1. PRISMA 
ﬂow diagram for 
cost studies in 
SLE.
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rect and indirect costs of SLE in patients 
with and without ﬂares. Total costs for 
patients who did not have ﬂares were 
$10,870 (direct costs: $6,034, indirect 
costs: $4,905), and for patients who 
had ﬂares amounted to $22,580 (direct 
costs: $16,873, indirect costs: $5,756). 
The main costs involved inpatient care, 
accounting for 40% of the total direct 
costs in patients who did not have ﬂares 
and 70% in patients with ﬂares (22).
Huscher et al. evaluate the direct and 
indirect costs of illness in SLE patients 
and in other rheumatologic diseases. 
Data refer to 844 SLE patients enrolled 
in the national database of the German 
collaborative centres in 2002. Using 
different methods of assessment, indi-
rect costs range between €6,518 and 
€14,411 and represent an important 
part of the total costs of SLE. Costs in-
crease with increased disease duration 
ranging from €11,349 when the disease 
duration is <5 years to €17,695 when 
the disease duration is >10 years. No 
signiﬁcant differences were observed 
between women and men (29). 
Studies comparing costs between coun-
tries have shown that mean annual indi-
rect costs in USA are $16,345, in Can-
ada $11,101, and in UK $12,925. The 
mean 4-year cumulative indirect costs 
attributed to diminished labor market 
are $56,745 in USA, $38,642 in Can-
ada, and $42,213 in UK. The indirect 
costs due to diminished non-labor mar-
ket activity amount to $5,249, $5,455, 
and $8,572 respectively (21, 28).
In the tri-nation study assessing the 
health consumption and health status of 
SLE patients in Canada, USA and UK, 
715 patients (Canada 231, USA 269, 
UK 215) followed in 6 tertiary care 
centres (two centres in each country) 
were evaluated. Mean cumulative di-
rect costs per patient over 4 years were: 
$15,845 in Canada, $20,244 in USA 
and $17,647 in UK. Mean changes in 
SLICC/ACR DI were 0.49 in Canada, 
0.63 in USA and 0.48 in UK. American 
patients incurred in higher healthcare 
expenditure, but did not experience su-
perior health outcomes (31).
The impact and costs of hospitalisations 
has been evaluated by Krishnan who 
examined the hospitalisation and mor-
tality outcomes of patients with SLE in 
the US from 1998 to 2002. The hospi-
talisation of patients with SLE includes 
76,961 persons, of whom 8,710 (11% 
of the total population) have SLE as the 
main reason of admission; 3.1% of hos-
pitalisations resulted in death. Patients 
with higher income and those with pri-
vate insurance have better mortality out-
comes than those with lower income or 
not having private insurance. The me-
dian hospital charge was $10,101, while 
the median charge for patients who died 
was $25,585 (30). As largely reported in 
the literature, SLE has an impact on pa-
tients quality of life and ability to work, 
this may determine high indirect costs. 
In this respect Campbell et al. analysed 
the impact of SLE in Carolina on em-
ployment, in particular work status and 
predictors of job loss, between 1997 in 
1999. A follow up study was completed 
in 2001  (24). The study found that 26% 
of patients and 9% of subjects without 
SLE, who were working the year before 
the diagnosis or corresponding reference 
year had stopped working at follow-up. 
Ninety-two percent of patients com-
pared to 40% of controls had stopped 
working due to their health status. The 
annual mean salary was higher in the 
control group compared to the patient 
group, $24,909 versus $21,540, respec-
tively. The average salary loss for par-
ticipants at risk of job loss was higher 
in patients compared to control subjects 
($5,113 vs. $750, respectively). Among 
subjects who were working there were 
no differences in terms of median work-
ing hours per week and months per year; 
however, health-related absences from 
work in the previous year were higher 
among patients (median days: 10 vs. 6 
in control group). Furthermore, 28% 
of patients compared to 7% of controls 
were unable to work for a period of 2 or 
more months.
Similarly Panopalis et al. estimate the 
healthcare costs associated with chang-
es in work productivity from a societal 
perspective in 812 patients from the 
US. The rate of employment ranged 
from 76.8% in the year of diagnosis to 
48.7% in the current year. Both direct 
healthcare costs and costs associated 
with changes in productivity are sub-
stantial and contribute signiﬁcantly to 
the SLE total cost (27) (Table I).
SLE patients with active disease and 
lupus nephritis utilise more healthcare 
resources compared with patients with 
inactive disease and without lupus ne-
phritis (19). 
In a study comparing healthcare costs 
and the loss of productivity in 141 pa-
tients with SLE who had and did not 
have SLE nephritis, followed in rheu-
matology specialty centres in Canada 
between 2004 and 2009, the annual 
cost of patients with lupus nephritis 
was $12,597 versus $10,585 in those 
without lupus nephritis. In addition, a 
higher cost of $14,224 was observed 
for patients with active lupus nephritis 
versus $9,142 in those with inactive lu-
pus nephritis (p<0,05). Additionally, a 
trend toward higher costs for patients 
with active disease but no nephritis 
with respect to patients with inactive 
disease was observed (12,666 versus 
7,551). A higher loss of productivity 
was observed among caregivers of lu-
pus nephritis patients (19).
Pellettier et al. compare healthcare re-
source utilisation and direct medical 
costs in patients with and without lupus 
nephritis over a period of 12 months 
identiﬁed from US health insurance 
between July 2006 and December 2008 
(20). A total of 15,590 patients (1,068 
patients with lupus nephritis and 14,522 
without lupus nephritis) were included 
in the study. Total 12 month direct costs 
for all patients with SLE amount to 
more than US$207 million ($13,305 per 
patient). Patients with lupus nephritis 
consume more healthcare resources in 
terms of pharmacy services ($6,029 vs. 
$3,190), outpatient services ($15,267 
vs. $6,202), and inpatient hospitalisa-
tion ($9,292 vs. $2,636, with a length of 
stay of 16.52 days vs. 9.69 days).
The longitudinal study of Li et al. as-
sesses the long term medical costs for 
patients with SLE, a subset of patients 
with lupus nephritis and a matched ref-
erence group with the same number of 
persons without the disease. The mean 
annual medical expenditure in year 1 in 
SLE group is $16,089 versus $27,463 in 
lupus nephritis patients versus $9,258 in 
the group without the disease. The costs 
for SLE group decrease in year 2, and 
subsequently increase yearly at an aver-
age rate of 16% until year 5 ($23,860). 
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Similarly, in SLE patients with LN, the 
cost decreases by 10% in year 2, fol-
lowed by a yearly increase of 31%; at 
year 5 the annual medical cost amounts 
to $50,578 (23). 
Furthermore, higher direct healthcare 
costs have been reported for patients 
with renal damage (25). In a subgroup 
analysis of the tri-nation study, Clarke 
et al. compare the costs and the quality 
of life (QoL) in SLE patients with and 
without renal damage (26). Seven hun-
dred and ﬁfteen patients were enrolled 
between July 1995 and February 1998 
at 6 tertiary care SLE clinics in Canada 
(231), USA (269), and UK (215). The 
authors report the costs according to 
the renal item of the SLICC/ACR DI 
(Systemic Lupus International Collabo-
rating Clinics/ACR Damage Index), 
which ranges from 0 to 3. The mean 4-
year cumulative direct costs per patient 
ranges from $20,337 in SLICC/ACR DI 
= 0 to $99,544 in SLICC/ACR DI = 3. 
The mean 4-year cumulative indirect 
costs per patient ranges from $62,828 in 
group = 0 to $73,750 in group = 3. For 
patients with a renal subscale score of 3, 
the majority of total costs are absorbed 
by hospitalisation and dialysis. 
Only one study assessed evaluated the 
direct and indirect costs of SLE and 
neuropsychiatric SLE (NPSLE) in 306 
patients in Hong Kong, of these 26.8% 
had a total of 108 NPSLE events. Pa-
tients are divided in 5 groups: 0 NPSLE 
(n=223 patients), ≥1 NPSLE (n=83 pa-
tients), with seizure (n=12 patients), 
with CVD (n=11) and with headache 
(n=15 patients). Mean annual total costs 
in SLE patients amount to $13,307. 
Mean annual costs in 0 NPSLE are 
$11,124, in ≥1 NPSLE are $19,174, 
in patients with seizure are $28,560, 
in patients with CVD are $25,051 and 
in patients with headache are $7715. 
Mean direct costs are the follow-
ing: in 0 NPSLE group $6,710, in ≥1 
NPSLE $12,316, in patients with sei-
zure are $21,920, in patients with CVD 
$19,719, and in patients with headache 
$4,977. From the study it emerges that 
patients with NPSLE incurred higher 
direct and indirect costs compared with 
patients without NPSLE (25).
To facilitate the comparison of the 
cost analysis of the studies included 
in the review, costs were converted to 
Euro-2012 (estimate at 17/07/2012). 
Costs in national currencies have been 
inﬂated to 2012 and currencies differ-
ent from Euro were converted to Euros 
(Table I). The Consumer Price Index 
(http://www.bls.gov/bls/inﬂation.htm ) 
and the Bank of Canada (http://www.
bankofcanada.ca/rates/related/infla-
tion-calculator/) were used respectively 
for inﬂating U.S. Dollars and Canadian 
dollars to 2012. Currency conversions 
from U.S. Dollars to Euro ($1=€0.81) 
and from Canadian Dollars to Euro 
($CAN=0,80) were calculated as of 
17/07/2012 (http://www.oanda.com/
lang/it).
Gaps and limitations in the literature
SLE is a disease with a relevant eco-
nomic burden on society, producing 
high direct, indirect and intangible 
costs. Direct costs of SLE include those 
related to professional fees, diagnostic 
procedures, and therapeutics provided 
in the emergency, hospital or outpatient 
Table I. Annual direct healthcare costs.
Author, year Country Results (Euro, 2012)
Chiu , 2010 (18) Taiwan Total study population 
  €1429
Aghdassi, 2010 (19) Canada Patients LN vs. patients LNN
  €10,646 vs. €8945
  Patients with active disease vs. patients without active 
  disease (with lupus nephritis)
  €12,020 vs. €7725
  Patients with active SLE vs. patients with inactive SLE  
  (without lupus nephritis)
  €10,703 vs. €6381
Pellettier, 2009 (20) USA Patients with nephritis vs. patients without nephritis 
  €26,731 vs. €10,489
Carls, 2009 (21) USA SLE group vs matched controls group
  €18,749 vs. €6984
  Patients without nephritis vs. matched control group
  €14,850 vs. €6556
  Patients with nephritis vs. matched control group
  €56,136 vs. 11,082
Zhu, 2009 (22) Hong Kong Patients with ﬂares vs. patients without ﬂares
  €15,715 vs. €5666
Li, 2009 (23) USA SLE patients vs. matched group vs. subgroup SLE with 
  nephritis
  €14,984 vs. €8622 vs. 25,578
Zhu, Tam (25)  Hong Kong SLE patients
  €7628
  0 NPSLE: €6218
  ≥1 NPSLE: €11,415
  With seizure: €20,316
  With CVD: €18,276
  With headache: €4613
Clarke, 2008 (26) Canada Patients without renal damage vs. with renal damage
  SLICC 0= €18,220
  SLICC 1= €24,969
  SLICC 2= €45,865
  SLICC 3= €89,187
Panopalis, 2008 (27) USA Total study population 
  €11,775
Huscher, 2006 (29) Germany SLE patients
  €3413
Clarke, 2004 (31)  Canada Cumulative medical direct cost over 4 years
  Canada: €15,661
  USA: €20,009
  UK: €17,443
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setting. Indirect costs include changes 
in work productivity (absenteeism and 
presenteeism), unpaid work (work in 
the home), psychological impact and 
quality of life decrements. The detec-
tion and evaluation of these costs is not 
easy because SLE is a chronic disease, 
with periods of activity and periods of 
remission. 
Although advances in therapy and man-
agement have occurred over the last dec-
ades, with a dramatic improvement of 
patient survival, SLE remains a morbid 
disease (43-46). Most patients accrue 
disease damage over time, and many 
have diminished quality of life (47). 
Poor outcomes are more common in 
racial/ethnic minorities and those with 
low socioeconomic status. Moreover, 
there are interesting studies reporting 
the social and work disability implica-
tions of SLE, measuring the number of 
working days lost. Between diagnosis 
and follow-up interview, the proportion 
employed declined from 74% to 54%. 
Over the same period, hours of work 
per year declined by 32.2% among all 
individuals with a work history, but 
by only 1% among those continuously 
employed (43). Until age 55 years, low 
rates of employment among persons 
with SLE may be due to lower rates of 
work entry rather than higher rates of 
work loss. Beyond age 55 years, both 
high rates of work loss and low rates 
of work entry contribute to low rates 
of employment (36). Rates of work 
loss were higher in those with cogni-
tive impairment (28) and in those with 
incident thrombosis, musculoskeletal 
manifestations, and increased levels of 
disease activity (33).  
Despite these facts, as we have shown, 
the literature evaluating disease costs 
remains limited and to date has only 
included a small number of countries. 
There are at least three main reasons 
– which are particularly important in 
public health care systems, where the 
government is the major payer – that 
may explain the paucity of data on eco-
nomic implications: a) the low preva-
lence of the disease, compared to other 
chronic rheumatic diseases such as 
rheumatoid arthritis; b) the relatively 
modest medication costs for most drugs 
currently used for the condition; c) the 
high impact of indirect costs, that do 
not bear on the health care payer.
In particular, one of the difﬁculties in 
determining disease costs is that the 
results of cost of illness studies are de-
pendent on how old the therapies are. In 
fact, with the exception of belimumab, 
all drugs used in SLE are old and off 
patent, this makes SLE seem cheaper 
than RA because RA has a lot of new, 
expensive drugs.
Moreover, most of the studies present 
too short a time horizon in respect to 
the chronic and progressive nature of 
SLE. Only a few articles consider a pe-
riod longer than one year (23, 33). How 
does the progression of the disease af-
fect resource utilisation and work dis-
ability over time? These questions re-
quire further analyses.
In spite of these limitations, available 
studies do illustrate that SLE has sig-
niﬁcant socio-economic ramiﬁcations. 
Future economic studies, especially 
those designed as long-term studies, in-
cluding more detailed segmentation of 
SLE patients, more comprehensive sets 
of cost categories, and more sophisti-
cated metrics for measuring QoL, are 
needed to provide important additional 
data (48).
Conclusion
SLE is a chronic, disabling, progres-
sive disease, with many associated co-
morbidities, that affects patients during 
prime working years resulting in a high 
economic burden on society, produc-
ing high direct, indirect and intangible 
costs.
Few studies have addressed the socio-
economic implications of SLE. Future 
studies are needed that take a more 
comprehensive approach to examine the 
socio-economic burden of SLE, one that 
carefully considers indirect costs as well 
as direct costs, and that adopts a longer 
time horizon, more coherent with the 
chronic and progressive nature of SLE.
The need for more sophisticated eco-
nomic analyses will continue to grow, 
especially in light of the number of novel 
Table II. Annual indirect costs.
   
Author, year Country Results (Euro, 2012)
Carls, 2009 (21) USA SLE group vs. matched control group
  Absenteeism costs in 12-mo study period
  €3335 vs. €3863
  Short term disability costs in 12-mo study period
  €2157 vs. €1019
  Patients without nephritis vs. matched control group
  €5492 vs. €3935
  Patients with nephritis vs. matched control group
  €5582 vs. €4747
Zhu, 2009 (22) Hong Kong Patients with ﬂares vs. patients without ﬂares
  €4568 vs. €5361
Campbell, 2009 (24) USA SLE patients vs. matched control group
  Average salary loss for all participants at risk of job loss
  €5398 vs. €791
Zhu, Tam (25)  Hong Kong SLE patients
  €4705
  0 NPSLE: €4091
  ≥1 NPSLE: €6357
  With seizure: €6154
  With CVD: €5127
  With headache: €2523
Clarke, 2008 (26) Canada Patients without renal damage vs. with renal damage
  SLICC 0= €56,290
  SLICC 1= €63,234
  SLICC 2= €60,011
  SLICC 3= €66,076
Panopalis, 2007 (28) USA SLE patients 
  USA: €17,059
  Canada: €11,586
  UK: €13,490
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biologic therapies that have entered the 
market or that are currently under inves-
tigation for SLE. As medication costs 
rise, payers, whether they are public or 
private entities, will be increasingly in-
terested in evaluating the budget impact 
of new treatments and their cost-effec-
tiveness in respect to standard thera-
pies. What will be the impact of the new 
therapies on the other direct health care 
costs (visits, admissions, emergency ac-
cesses, costs of treating comorbidities, 
etc.), and on the indirect and intangible 
costs? How will these analyses affect 
reimbursement decisions? These are 
relevant questions for stakeholders. 
Future studies should focus on the cost-
effectiveness and cost-utility analyses 
of different therapeutic approaches, in-
cluding a comprehensive set of costs.
An interesting issue in these new eco-
nomic evaluations in SLE may be rep-
resented by the selection of the targets 
of the treatment to include in the cost-
effectiveness and cost-utility analyses 
(47). Future treat-to-target strategies 
will likely be evaluated with respect to 
their economic implications. 
The current debate over new drugs in-
creases the urgency for the economic 
research in SLE to progress rapidly.
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